A Case Study in the Risks of Marijuana Biotech

Regular readers of MJINews hardly need to be persuaded that the growth of the legal marijuana market has made a number of entrepreneurs and their investors a lot of money. It will yet do more of the same. In another five years the industry could show total revenues of $35 billion, if all 50 states and Washington, D.C., legalize retail marijuana.  

But … there is no profit without risk, and it is well for those who would invest in this field, either capital or entrepreneurial energy or both, that they recognize the risk.

The valuation reversal suffered by Abattis Bioceuticals (OTCQX: ATTBF), a Vancouver-based biotech company aspiring to compete in the entire marijuana industry supply chain from seed to consumer sale, illustrates that point of risk vividly. For a brief period in mid-July 2014, ATTBF traded at between $0.60 and $0.70 per share. Less than a year later it is trading...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.mjinews.com/case-study-risks-marijuana-biotech/